INCB88888-040 Multicenter Prospective Real-world Observational Cohort Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
Latest Information Update: 24 May 2024
At a glance
- Drugs Lenalidomide (Primary) ; Tafasitamab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms PRO-MIND
- Sponsors Incyte Biosciences Italy
Most Recent Events
- 12 Mar 2024 New trial record